source
- Minghui Pharma sells Japanese rights to its Phase 3 thyroid eye disease drug for $110 million upfrontMinghui Pharmaceutical, a Shanghai‑based biotech, has agreed to transfer the Japanese commercial rights for its late‑stage thyroid eye disease candidate to a specialty pharmaceutical company. The…
- China targets five $1 billion blockbuster drugs by 2030, two already achievedChina's latest five-year plan aims to develop five domestically created drugs that each generate over $1 billion in global sales by 2030. According to industry analysts, two drugs have already sur…